{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:31:27Z","timestamp":1792801887383,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Paula and Roger Riney Foundation","id":[{"id":"https:\/\/ror.org\/050a7g229","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR000135"],"award-info":[{"award-number":["UL1 TR000135"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA254961"],"award-info":[{"award-number":["CA254961"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Marion Schwarz Foundation for Multiple Myeloma"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Metab"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aimed to evaluate the metabolic differences between MM cells derived from patients with elevated serum LDH levels and those without elevated serum LDH levels to identify biological differences that could be exploited for therapeutic purposes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed transcriptome assessments of CD138\u2009+\u2009MM cells derived from patients with elevated serum LDH levels compared to those without elevated serum LDH levels and validated the findings in a larger public dataset. Functional metabolic assessments of our findings were performed using a combination of stable isotope resolved metabolomics (SIRM), bioenergetic flux measurement assays, and live cell analysis in human myeloma cell lines and primary MM patient cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We identified\n                      <jats:italic>SLC16A1<\/jats:italic>\n                      , responsible for the formation of MCT1, a well-defined bi-directional transporter of lactate in and out of a cell with a predilection to importing extracellular lactate, as differentially expressed between the two groups. This finding was functionally confirmed by higher membranous MCT1 protein expression and SIRM on MM cells derived from patients with elevated serum LDH levels compared to those without elevated serum LDH levels. Finally, disrupting lactate transport in and out of CD138\u2009+\u2009MM cells was maximally achievable only with dual inhibition of MCT1 and its partner, MCT4, which was preferentially more cytotoxic in MM cells derived from patients with elevated serum levels of LDH.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MCT1 mRNA and protein expression distinguish MM cells derived from patients with elevated serum LDH levels from those without elevated serum LDH levels. However, only dual inhibition of MCT1 and MCT4 can disrupt lactate transport in multiple myeloma (MM) cells, with preferential cytotoxicity in MM cells from patients with high serum LDH levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40170-025-00379-1","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:56:50Z","timestamp":1739440610000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Lactate metabolism in clonal plasma cells and its therapeutic implications in multiple myeloma patients with elevated serum LDH levels"],"prefix":"10.1186","volume":"13","author":[{"given":"Yogesh","family":"Chawla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie I.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura A.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jadee","family":"Neff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Sung","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isas K.","family":"Vazquez Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Mai","family":"Petterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinto","family":"Sebastian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Hitosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"379_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21\u201333.","journal-title":"Mayo Clin Proc"},{"key":"379_CR2","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1111\/bjh.17925","volume":"196","author":"M Stork","year":"2022","unstructured":"Stork M, Sevcikova S, Minarik J, et al. Identification of patients at high risk of secondary extramedullary multiple myeloma development. Br J Haematol. 2022;196:954\u201362.","journal-title":"Br J Haematol"},{"key":"379_CR3","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1600-0609.2010.01466.x","volume":"85","author":"E Terpos","year":"2010","unstructured":"Terpos E, Katodritou E, Roussou M, et al. High serum lactate dehydrogenase adds prognostic value to the international myeloma staging system even in the era of novel agents. Eur J Haematol. 2010;85:114\u20139.","journal-title":"Eur J Haematol"},{"key":"379_CR4","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1124\/pr.119.018762","volume":"72","author":"MA Felmlee","year":"2020","unstructured":"Felmlee MA, Jones RS, Rodriguez-Cruz V, et al. Monocarboxylate transporters (SLC16): function, regulation, and role in Health and Disease. Pharmacol Rev. 2020;72:466\u201385.","journal-title":"Pharmacol Rev"},{"key":"379_CR5","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nature24057","volume":"551","author":"S Hui","year":"2017","unstructured":"Hui S, Ghergurovich JM, Morscher RJ, et al. Glucose feeds the TCA cycle via circulating lactate. Nature. 2017;551:115\u20138.","journal-title":"Nature"},{"key":"379_CR6","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1158\/1078-0432.CCR-13-2270","volume":"20","author":"R Polanski","year":"2014","unstructured":"Polanski R, Hodgkinson CL, Fusi A, et al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res. 2014;20:926\u201337.","journal-title":"Clin Cancer Res"},{"key":"379_CR7","doi-asserted-by":"crossref","unstructured":"Cluntun AA, Badolia R, Lettlova S et al. The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure. Cell Metab 33:629\u201348 e10, 2021.","DOI":"10.1016\/j.cmet.2020.12.003"},{"key":"379_CR8","doi-asserted-by":"crossref","unstructured":"Benjamin D, Robay D, Hindupur SK et al. Dual inhibition of the Lactate transporters MCT1 and MCT4 is Synthetic Lethal with Metformin due to NAD\u2009+\u2009depletion in Cancer cells. Cell Rep 25:3047\u201358 e4, 2018.","DOI":"10.1016\/j.celrep.2018.11.043"},{"key":"379_CR9","doi-asserted-by":"crossref","unstructured":"Gonsalves WI, Ramakrishnan V, Hitosugi T et al. Glutamine-derived 2-hydroxyglutarate is associated with disease progression in plasma cell malignancies. JCI Insight 3, 2018.","DOI":"10.1172\/jci.insight.94543"},{"key":"379_CR10","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40170-020-00235-4","volume":"8","author":"WI Gonsalves","year":"2020","unstructured":"Gonsalves WI, Jang JS, Jessen E, et al. In vivo assessment of glutamine anaplerosis into the TCA cycle in human pre-malignant and malignant clonal plasma cells. Cancer Metab. 2020;8:29.","journal-title":"Cancer Metab"},{"key":"379_CR11","doi-asserted-by":"crossref","unstructured":"Mishra D, Banerjee D. Lactate dehydrogenases as metabolic links between Tumor and Stroma in the Tumor Microenvironment. Cancers (Basel) 11, 2019.","DOI":"10.3390\/cancers11060750"},{"key":"379_CR12","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1182\/blood-2018-99-115523","volume":"132","author":"S Bal","year":"2018","unstructured":"Bal S, Girnius SK, Starczynowski DT, et al. Genomic Landscape of multiple myeloma with elevated lactate dehydrogenase. Blood. 2018;132:470\u2013470.","journal-title":"Blood"},{"key":"379_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34:355\u201377.","journal-title":"Cell Metab"},{"key":"379_CR14","doi-asserted-by":"crossref","unstructured":"Faubert B, Li KY, Cai L et al. Lactate Metabolism in Human Lung tumors. Cell 171:358\u201371 e9, 2017.","DOI":"10.1016\/j.cell.2017.09.019"},{"key":"379_CR15","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s40164-015-0008-z","volume":"4","author":"S Fujiwara","year":"2015","unstructured":"Fujiwara S, Wada N, Kawano Y, et al. Lactate, a putative survival factor for myeloma cells, is incorporated by myeloma cells through monocarboxylate transporters 1. Exp Hematol Oncol. 2015;4:12.","journal-title":"Exp Hematol Oncol"},{"key":"379_CR16","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","volume":"25","author":"RM Peralta","year":"2024","unstructured":"Peralta RM, Xie B, Lontos K, et al. Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nat Immunol. 2024;25:2297\u2013307.","journal-title":"Nat Immunol"},{"key":"379_CR17","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-024-00535-1","volume":"13","author":"A Van der Vreken","year":"2024","unstructured":"Van der Vreken A, Vanderkerken K, De Bruyne E, et al. Fueling CARs: metabolic strategies to enhance CAR T-cell therapy. Exp Hematol Oncol. 2024;13:66.","journal-title":"Exp Hematol Oncol"},{"key":"379_CR18","doi-asserted-by":"crossref","unstructured":"Lopez E, Karattil R, Nannini F et al. Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies. J Immunother Cancer 11, 2023.","DOI":"10.1136\/jitc-2022-006287"},{"key":"379_CR19","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1093\/emboj\/19.15.3896","volume":"19","author":"P Kirk","year":"2000","unstructured":"Kirk P, Wilson MC, Heddle C, et al. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000;19:3896\u2013904.","journal-title":"EMBO J"},{"key":"379_CR20","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/onc.2015.360","volume":"35","author":"L Gan","year":"2016","unstructured":"Gan L, Xiu R, Ren P, et al. Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters. Oncogene. 2016;35:3037\u201348.","journal-title":"Oncogene"},{"key":"379_CR21","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1158\/0008-5472.CAN-11-2474","volume":"72","author":"R Boidot","year":"2012","unstructured":"Boidot R, Vegran F, Meulle A, et al. Regulation of monocarboxylate transporter MCT1 expression by p53 mediates inward and outward lactate fluxes in tumors. Cancer Res. 2012;72:939\u201348.","journal-title":"Cancer Res"},{"key":"379_CR22","doi-asserted-by":"publisher","first-page":"3175","DOI":"10.4161\/cc.26193","volume":"12","author":"DK Walters","year":"2013","unstructured":"Walters DK, Arendt BK, Jelinek DF. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle. 2013;12:3175\u201383.","journal-title":"Cell Cycle"},{"key":"379_CR23","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1038\/leu.2015.191","volume":"30","author":"S Panchabhai","year":"2016","unstructured":"Panchabhai S, Kelemen K, Ahmann G, et al. Tumor-associated macrophages and extracellular matrix metalloproteinase inducer in prognosis of multiple myeloma. Leukemia. 2016;30:951\u20134.","journal-title":"Leukemia"},{"key":"379_CR24","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3324\/haematol.2016.163030","volume":"102","author":"RA Noble","year":"2017","unstructured":"Noble RA, Bell N, Blair H, et al. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2017;102:1247\u201357.","journal-title":"Haematologica"},{"key":"379_CR25","doi-asserted-by":"publisher","first-page":"69219","DOI":"10.18632\/oncotarget.18215","volume":"8","author":"NJ Curtis","year":"2017","unstructured":"Curtis NJ, Mooney L, Hopcroft L, et al. Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt\u2019s lymphoma anti-tumor activity. Oncotarget. 2017;8:69219\u201336.","journal-title":"Oncotarget"},{"key":"379_CR26","doi-asserted-by":"publisher","first-page":"33568","DOI":"10.18632\/oncotarget.5598","volume":"6","author":"DJ Hanson","year":"2015","unstructured":"Hanson DJ, Nakamura S, Amachi R, et al. Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation. Oncotarget. 2015;6:33568\u201386.","journal-title":"Oncotarget"},{"key":"379_CR27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nm.4128","volume":"22","author":"R Eichner","year":"2016","unstructured":"Eichner R, Heider M, Fernandez-Saiz V, et al. Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity. Nat Med. 2016;22:735\u201343.","journal-title":"Nat Med"},{"key":"379_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1182\/bloodadvances.2021005532","volume":"6","author":"J Stroh","year":"2022","unstructured":"Stroh J, Seckinger A, Heider M, et al. MCT1 is a predictive marker for lenalidomide maintenance therapy in multiple myeloma. Blood Adv. 2022;6:515\u201320.","journal-title":"Blood Adv"},{"key":"379_CR29","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/path.6066","volume":"260","author":"A Van der Vreken","year":"2023","unstructured":"Van der Vreken A, Oudaert I, Ates G, et al. Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis. J Pathol. 2023;260:112\u201323.","journal-title":"J Pathol"},{"key":"379_CR30","doi-asserted-by":"publisher","first-page":"e1601756","DOI":"10.1126\/sciadv.1601756","volume":"2","author":"D Benjamin","year":"2016","unstructured":"Benjamin D, Colombi M, Hindupur SK, et al. Syrosingopine sensitizes cancer cells to killing by metformin. Sci Adv. 2016;2:e1601756.","journal-title":"Sci Adv"},{"key":"379_CR31","doi-asserted-by":"publisher","first-page":"532","DOI":"10.4065\/mcp.2009.0677","volume":"85","author":"P Kapoor","year":"2010","unstructured":"Kapoor P, Fonseca R, Rajkumar SV, et al. Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapie. Mayo Clin Proc. 2010;85:532\u20137.","journal-title":"Mayo Clin Proc"},{"key":"379_CR32","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1038\/bcj.2012.37","volume":"2","author":"A Kalff","year":"2012","unstructured":"Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012;2:e89.","journal-title":"Blood Cancer J"},{"key":"379_CR33","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"}],"container-title":["Cancer &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00379-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40170-025-00379-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40170-025-00379-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T09:57:04Z","timestamp":1739440624000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerandmetabolism.biomedcentral.com\/articles\/10.1186\/s40170-025-00379-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["379"],"URL":"https:\/\/doi.org\/10.1186\/s40170-025-00379-1","relation":{},"ISSN":["2049-3002"],"issn-type":[{"value":"2049-3002","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted with approval of the Mayo Clinic Institutional Review Board and in accordance with the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no potential conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"9"}}